Subtitle
Toxicity with proton therapy for oral and/or oropharyngeal cancers: A scoping review.
Subtitle
Toxicity with proton therapy for oral and/or oropharyngeal cancers: A scoping review.
Proto therapy Time
August 2023
Executive summary
This review included 18 primary studies for analysis focusing on acute toxicities including dysphagia, radiation dermatitis, oral mucositis, dysgeusia and alopecia. The conclusion made in this review is that current evidence supports that proton therapy improves acute toxicity profile compared to photon radiotherapy to treat oral and/or oropharyngeal cancer individuals.
Key content topics
Top cancer treatments
Related contents
Proton Therapy Publication
March 2024
A multicenter high-quality data registry for advanced proton therapy approaches: the POWER registry.
Proton Therapy Publication
April 2024
FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?
Proton Therapy Publication
April 2024
Proton FLASH radiotherapy ameliorates radiation-induced salivary gland dysfunction and oral mucositis and increases survival in a mouse model of head and neck cancer.
Proton Therapy Publication
April 2024
Comprehensive radiotherapy for pediatric Ewing Sarcoma: Outcomes of a prospective proton study.
Proton Therapy Publication
March 2024
Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis. This review.
Proton Therapy Publication
February 2024
Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer.
Proton Therapy Publication
April 2024
Long-term survival outcomes and quality of life of image-guided proton therapy for operable stage I non-small cell lung cancer: A phase 2 study.
Proton Therapy Publication
March 2024
Efficacy and toxicity of photon, proton, and carbon ion radiotherapy in the treatment of intracranial solitary fibrous tumor/hemangiopericytoma.
Proton Therapy Publication
January 2024
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.